- Fee assured
- Verified this account
Dr Ian Gabriel is the Lead Clinician for haematological cancers at Chelsea and Westminster Hospital. He qualified in medicine from St Marys Hospital Medical School - Imperial College in 1999 and completed his specialist training in haematology in London. He was awarded the Frank Cass Scholarship to pursue research and completed his PhD at Imperial College, researching the role of killer immunoglobulin receptors in post-transplant tumour eradication (myeloma and CML) and and graft versus host reactions.
Ian holds a joint consultant position with Imperial College NHS Healthcare Trust (Hammersmith Hospital) where he is a consultant in haemato-oncology and stem cell transplantation (autologous and allogeneic transplant).
His main interest is in haemato-oncology and stem cell transplantation. He is a founder member of the European Consortium for Stem Cell Mobilisation (ECOSM), and member of the lymphoma working party of the European
Blood and Marrow Transplant Group (EBMT).
His areas of particular interest are lymphoma, transplantation for cutaneous T-cell lymphomas, and the late effects of transplant.
Ian has an interest in the haematological complications of HIV infection and runs a newly
created HIV-haematology joint clinic at Chelsea and Westminster.He also runs a general haematology clinic inclduing anti-coagulation.
Dr Gabriel has published peer reviewed papers on lymphoma, myeloma, and leukaemia in addition to those on stem cell transplantation. He is the author of a number of book chapters.
Areas of interest
Haematological malignancy lymphoma, leukaemia, myeloma, myelodysplasia, myeloproliferative disordesr stem cell transplantation; stem cell transplantation for multiple sclerosis, general haematology;anticoagulation
Current NHS consultant posts held
Consultant haematologist - Chelsea and Westminster Hospital - lead clinician for haematological cancer
Consultant haematologist - Imperial College NHS Healthcare Trust (Hammsermith Hospital)
His main interest is in haemato-oncology and stem cell transplantation.
Particular areas of interest include are transplantation for cutaneous T-cell lymphomas, the late effects of transplantation, Natural Killer cell biology and haematological effects of HIV infection.
Smith and Nephew Pharmaceuticals Scholarship for research.
The Frank Cass Scholarship for postgraduate research
Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients with Mycosis Fungoides and Sézary Syndrome: An EBMT Lymphoma Working Party Extended analysis. Journal of Clinical Oncology
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with Imatinib. Leukaemia
Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood
Autologous stem-cell transplantation in patients with HIV-related lymphoma.Journal of Clinical Oncology
Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplant procedure. Biology of Blood and Marrow transplant
European Data on Stem Cell Mobilization with Plerixafor in Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Multiple Myeloma Patients. Bone Marrow Transplant
Plerixafor for autologous peripheral blood stem cells mobilization in patients previously treated with fludarabine or lenalidomide. Biology of Blood and Marrow transplant
Tyrosine kinase inhibitors impair B-cell immune response in CML through off-target kinases important for cell signalling. Blood
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood
Higher BMI is not a barrier to stem cell mobilization with standard doses of Plerixafor and G-CSF. Bone Marrow Transplant
European Data on Stem Cell Mobilization with Plerixafor in Patients with Non-Hematologic Diseases Transfusion.
Pulmonary Complications of Sickle Cell Disease. Airways
A long-term durable remission with high dose therapy autologous stem cell transplant for Stage IVB HIV-associated Hodgkin’s disease. AIDS
Graft Versus Lymphoma Effect after Early Relapse following Reduced Intensity Sibling Allogeneic Stem Cell Transplantation for Relapsed Cytotoxic Variant of Mycosis Fungoides. Bone Marrow Transplant
- MB BS MRCP(UK) FRCPath BSc(Hons) PhD St Mary’s Hospital Medical School - Imperial College 1999
Reference number 4642514
Affiliations / memberships
British Society of Haematology, Royal College of Pathologists, European Group for Blood and Marrow Transplantation, European Consortium for Stem Cell Mobilisation, British HIV Association.
- Chelsea & Westminster Hospital, SW10 9NH
- 07:30 - 20:00
- 020 3313 58211
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Dr Ian Gabriel 07825448725